Structure Therapeutics
Specializes in the discovery and development of drugs against a type of targets called GPCR.
Launch date
Employees
Market cap
$2.3b
Enterprise valuation
$1.4b (Public information from Sep 2024)
Share price
$38.26 GPCR
South San Francisco California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 55.6m | - |
| EBITDA | (<1m) | (<1m) | (52.6m) | (102m) | (162m) | (181m) | (218m) |
| % EBITDA margin | - | - | - | - | - | (325 %) | - |
| Profit | (<1m) | (<1m) | (51.3m) | (89.6m) | (123m) | (110m) | (229m) |
| % profit margin | - | - | - | - | - | (198 %) | - |
| EV / revenue | - | - | - | - | - | 36.5x | - |
| EV / EBITDA | - | - | - | -19.4x | -11.3x | -11.2x | -8.7x |
| R&D budget | <1m | <1m | 36.2m | 70.1m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$16.0m | Series A | ||
$26.0m | Series A | ||
$100m | Series B | ||
* | $33.0m Valuation: $500m -13289.4x EV/LTM EBITDA | Series B | |
* | N/A | $161m | IPO |
* | N/A | $300m | Private Placement VC |
* | N/A | $476m | Post IPO Equity |
| Total Funding | $475m | ||
Related Content
Recent News about Structure Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.